This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Vincent, G. M. Search for Related Content PubMed PubMed Citation Articles by Vincent, G. M. Related Collections Arrhythmias, clinical electrophysiology, drugs Clinical genetics Other diagnostic testing Related Article

Controversies in Arrhythmia and Electrophysiology

Genotyping Has a Minor Role in Selecting Therapy for Congenital Long-QT Syndromes at Present

G. Michael Vincent, MD

From the LDS Hospital, Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT.

Correspondence to G. Michael Vincent, MD, Inherited Arrhythmia Program, 324 10th Avenue, Suite 127, Salt Lake City, UT 84103. E-mail g.vincent@imail.org

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Genotyping has led to enormous advances in understanding the phenotype and clinical course of the congenital long-QT syndromes (LQTS). In the most common LQTS forms, LQT1, LQT2, and LQT3, genotyping a clearly affected person in each family provides the ability to easily identify family members with reduced penetrance of the QTc and symptoms phenotypes, thus, providing also the opportunity to prevent sudden death and cardiac arrest by administering presymptomatic therapy.

Response by Moss and Goldberg see p 227

The role of genotyping in selecting the therapy for LQTS is, on the other hand, unclear. Data from the literature and from the Salt Lake City LQTS database will be presented to show that genotyping has only a minor role in selecting therapy for LQTS. The discussion will primarily address the LQT1, LQT2, and LQT3 forms (caused by mutations of the LQT1, 2, 3, 5, and 6 genes)¹ and the rare LQT4, LQT7, and LQT8 forms will be discussed briefly, and because so little is known about the new LQT9-11 forms they are not ready for a discussion of genotyping for therapy decisions. The pleural term "Long-QT syndromes" is indeed now very appropriate because of the diversity (both molecular and phenotype) of the conditions caused by the 11 accepted or proposed LQTS genes.

	What Is the Role of Genotyping for Selecting Therapy for Congenital Long-QT Syndrome?

 
The idea of genotype-based therapy has been discussed for some time, being encouraged by the experimental findings with mexiletine and flecainide in LQT3 and potassium supplementation in LQT2, plus other laboratory findings.^2–8 The concept has received additional attention recently . . . [Full Text of this Article]

Related Article

Genotyping Has a Minor Role in Selecting Therapy for Congenital Long-QT Syndromes at Present

G. Michael Vincent
Circ Arrhythm Electrophysiol 2008 1: 227-233. [Extract] [Full Text] [PDF]